{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:56:10Z","timestamp":1790837770252,"version":"4.1.0"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Idiopathic inflammatory myopathies (IIM) are systemic autoimmune rheumatic diseases in which interstitial lung disease (ILD) is a frequent extra-muscular manifestation and a major driver of morbidity and mortality. ILD occurs most commonly in antisynthetase syndrome and anti\u2013melanoma differentiation-associated gene 5 (anti-MDA5) dermatomyositis syndrome, the latter carrying a high risk of rapidly progressive ILD (RP-ILD). Although recent guidelines outline conventional immunosuppressive strategies, a subset of patients progress despite escalation, and the definition of refractory IIM-ILD remains poorly standardized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Because type I and II interferon signaling, other cytokines, and aberrant B-cell activity have been implicated in the pathogenesis of IIM-ILD, novel therapies have been used off-label to target these mechanisms in treatment-resistant disease. This review summarizes emerging off-label and investigational therapies, including Janus kinase inhibitors, direct cytokine inhibitors (anifrolumab, dazukibart, tocilizumab, basiliximab), B-cell\u2013 and plasma-cell\u2013targeted approaches (anti-CD20 antibodies, daratumumab, chimeric antigen receptor T-cell therapy, bispecific T-cell engagers), intravenous immunoglobulin, and antifibrotics, and rescue measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Across these agents, evidence is confined to case reports, small series, and observational cohorts, with few randomized trials reporting IIM-ILD-specific outcomes. Prospective studies are needed to define patient selection, treatment sequencing and combinations, durability, and safety of novel therapies in IIM-ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001194","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:18:26Z","timestamp":1788949106000},"page":"499-508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease"],"prefix":"10.1097","volume":"38","author":[{"given":"Laurence","family":"Poirier-Blanchette","sequence":"first","affiliation":[{"name":"Division of Rheumatology"},{"name":"Centre de Recherche du Centre Hospitalier Universitaire de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u2019ama","family":"Avitzur","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia"},{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital, Vancouver, BC"},{"name":"Division of Respirology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Krustev","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"},{"name":"Department of Microbiology, Immunology and Infectious Diseases"},{"name":"McCaig Institute for Bone and Joint Health"},{"name":"Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMra2415426","article-title":"Inflammatory myopathies","volume":"394","author":"Allenbach","year":"2026","journal-title":"N Engl J Med"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)","volume":"85","author":"Antoniou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: management of refractory inflammatory myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","article-title":"Clinical features and outcome of patients with acute respiratory failure revealing antisynthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study","volume":"8","author":"Vuillard","year":"2018","journal-title":"Ann Intensive Care"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"e0154441","DOI":"10.1371\/journal.pone.0154441","article-title":"Dermatomyositis and polymyositis in the intensive care unit: a single-center retrospective cohort study of 102 patients","volume":"11","author":"Peng","year":"2016","journal-title":"PLoS One"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by antimelanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"e90010","DOI":"10.1002\/acr2.90010","article-title":"Clinical characteristics and evolution of interstitial lung disease in subtypes of idiopathic inflammatory myositis with prevalent lung manifestation: a retrospective analysis","volume":"8","author":"Clark","year":"2026","journal-title":"ACR Open Rheumatol"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"116137","DOI":"10.1016\/j.intimp.2025.116137","article-title":"Baricitinib alleviates myositis-associated interstitial lung disease in mice by inhibiting the NETs-cGAS-STING-EMT axis","volume":"171","author":"Guo","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in antimelanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"2401488","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"1658547","DOI":"10.3389\/fimmu.2025.1658547","article-title":"Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"1568338","DOI":"10.3389\/fimmu.2025.1568338","article-title":"A pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy","volume":"16","author":"Tokunaga","year":"2025","journal-title":"Front Immunol"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/resp.70248","article-title":"Upadacitinib versus tofacitinib in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicentre cohort study emulating a target trial","volume":"7","author":"Xia","year":"2026","journal-title":"Respirology"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"e003837","DOI":"10.1136\/rmdopen-2023-003837","article-title":"Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients","volume":"10","author":"Beckett","year":"2024","journal-title":"RMD Open"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"152474","DOI":"10.1016\/j.semarthrit.2024.152474","article-title":"Janus kinase inhibition (JAKi) therapy in refractory antisynthetase syndrome: a retrospective cohort study","volume":"68","author":"Shan","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R26-20261001","first-page":"297","article-title":"Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series","volume":"44","author":"Vasconcelos","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"R27-20261001","first-page":"e49809","article-title":"The lack of a durable response to tofacitinib in anti-PL-12 antisynthetase syndrome with progressive interstitial pneumonitis","volume":"15","author":"Baldawi","year":"2023","journal-title":"Cureus"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2503531","article-title":"A phase 3 trial of brepocitinib in dermatomyositis","volume":"394","author":"Vleugels","year":"2026","journal-title":"N Engl J Med"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for antimelanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"103334","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2023","journal-title":"JAAD Case Rep"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3899\/jrheum.2025-0773","article-title":"Anifrolumab therapy in dermatomyositis: new insights from refractory patients","volume":"53","author":"Carli","year":"2025","journal-title":"J Rheumatol"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"keaf662","DOI":"10.1093\/rheumatology\/keaf662","article-title":"Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre\u2013multidisciplinary retrospective study","volume":"65","author":"Retuerto-Guerrero","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"1717766","DOI":"10.3389\/fimmu.2025.1717766","article-title":"Efficacy of anifrolumab on skin, joint and lung involvement in anti-MDA5 positive dermatomyositis: a case report","volume":"16","author":"Pettorossi","year":"2025","journal-title":"Front Immunol"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/atm-25-44","article-title":"Dazukibart for dermatomyositis: expanding the therapeutic arsenal","volume":"13","author":"Pinal-Fernandez","year":"2025","journal-title":"Ann Transl Med"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/jdv.70343","article-title":"Compassionate use efficacy of the interferon-beta inhibitor dazukibart in dermatomyositis","volume":"40","author":"Vleugels","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40744-018-0102-x","article-title":"A review of recent advances using tocilizumab in the treatment of rheumatic diseases","volume":"5","author":"Rubbert-Roth","year":"2018","journal-title":"Rheumatol Ther"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"1497168","DOI":"10.3389\/fped.2024.1497168","article-title":"Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review","volume":"12","author":"Qiu","year":"2024","journal-title":"Front Pediatr"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3390\/jcm9103070","article-title":"Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review","volume":"9","author":"Atienza-Mateo","year":"2020","journal-title":"J Clin Med"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2665-9913(24)00338-2","article-title":"Evolution and trajectory of B-cell targeted therapies in rheumatic diseases","volume":"7","author":"Carter","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"1581323","DOI":"10.3389\/fimmu.2025.1581323","article-title":"Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies","volume":"16","author":"Groener","year":"2025","journal-title":"Front Immunol"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"(Suppl 11)","key":"R50-20261001","article-title":"Experience on the use of obinutuzumab off label in patients with refractory idiopathic inflammatory myopathy [abstract]","volume":"76","author":"Ilic","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R51-20261001","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1093\/rheumatology\/kead424","article-title":"Antisignal recognition particle antibody-positive immune-mediated necrotizing myopathy treated with ofatumumab","volume":"63","author":"Wen","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R52-20261001","article-title":"Failure of daratumumab in the treatment of antisynthetase syndrome: a case report","volume":"13","author":"Nguyen","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"R53-20261001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"key":"R54-20261001","first-page":"460","article-title":"Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab","volume":"42","author":"Chua","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R55-20261001","doi-asserted-by":"crossref","first-page":"e003238","DOI":"10.1136\/rmdopen-2023-003238","article-title":"Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"R56-20261001","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/ard-2022-223541","article-title":"Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy","volume":"82","author":"Landon-Cardinal","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R57-20261001","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41591-026-04430-6","article-title":"Resetting autoimmune disease with CAR cell therapies","volume":"32","author":"Schett","year":"2026","journal-title":"Nat Med"},{"key":"R58-20261001","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"R59-20261001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"R60-20261001","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","article-title":"A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy\u2014case report and literature review","volume":"64","author":"Haase","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R61-20261001","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"R62-20261001","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","article-title":"Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases","volume":"32","author":"D\u00fcsing","year":"2026","journal-title":"Nat Med"},{"key":"R63-20261001","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ard.2026.02.002","article-title":"Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series","volume":"85","author":"Scherlinger","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R64-20261001","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"R65-20261001","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of antimelanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R66-20261001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"R67-20261001","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.3390\/jcm13206085","article-title":"Myositis-associated interstitial lung disease: the experience of a tertiary center","volume":"13","author":"Correia","year":"2024","journal-title":"J Clin Med"},{"key":"R68-20261001","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R69-20261001","doi-asserted-by":"crossref","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R70-20261001","first-page":"386","article-title":"Nintedanib could potentially lead to improvements in antimelanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease","volume":"42","author":"Chen","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"R71-20261001","first-page":"e70497","article-title":"Pirfenidone as a cornerstone in the management of fibrotic interstitial lung diseases and its emerging applications: a comprehensive review","volume":"16","author":"Babariya","year":"2024","journal-title":"Cureus"},{"key":"R72-20261001","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"R73-20261001","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"R74-20261001","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211060907","article-title":"Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease","volume":"13","author":"Wilfong","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R75-20261001","doi-asserted-by":"crossref","first-page":"152564","DOI":"10.1016\/j.semarthrit.2024.152564","article-title":"One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease\u2014a systematic review and meta-analysis","volume":"69","author":"Tangborwornweerakul","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R76-20261001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2169\/internalmedicine.1410-22","article-title":"Early initiation of plasma exchange therapy for anti-MDA5(+) dermatomyositis with refractory rapidly progressive interstitial lung disease","volume":"63","author":"Sasaki","year":"2024","journal-title":"Intern Med"},{"key":"R77-20261001","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R78-20261001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03009742.2021.1995984","article-title":"Efficacy and safety of plasma exchange in interstitial lung diseases with antimelanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis","volume":"52","author":"Komai","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"R79-20261001","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.jaut.2022.102941","article-title":"Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease","volume":"133","author":"Bay","year":"2022","journal-title":"J Autoimmun"},{"key":"R80-20261001","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R81-20261001","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/1744-9987.14106","article-title":"Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: a case series","volume":"28","author":"Watanabe","year":"2024","journal-title":"Ther Apher Dial"},{"key":"R82-20261001","doi-asserted-by":"crossref","first-page":"keag200","DOI":"10.1093\/rheumatology\/keag200","article-title":"Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicentre retrospective analysis","volume":"65","author":"Chang","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"R83-20261001","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keae311","article-title":"Extracorporeal membrane oxygenation for acute lung injury in idiopathic inflammatory myopathies\u2014a potential lifesaving intervention","volume":"64","author":"Zheng","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:48Z","timestamp":1790834568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001194","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}